FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092895836> ?p ?o ?g. }

• W2092895836 endingPage "e69" @default.
• W2092895836 startingPage "e68" @default.
• W2092895836 abstract "Serum sickness (SS) after antithymocyte globulin (ATG) administration is documented in liver, pancreas, and renal transplants along with aplastic anemia (1–4). To our knowledge, although a few SS cases in the adult cardiac transplant population are reported online, none have been previously documented in the scientific literature. CLINICAL HISTORY A 57-year-old gentleman with allo-geneic heart transplantation for nonischemic cardiomyopathy developed nonspecific graft dysfunction 3 years posttransplant. He had no documented cellular or antibody-mediated rejection, graft vasculopathy, and donor-specific antibodies on panel reactive antibody testing. Plasmapheresis and IV immunoglobulin infusions were initiated in addition to increases in maintenance immuno-suppression therapy with no significant impact on his reduced ejection fraction. Because of recurrent presentations of decompensated heart failure despite escalation of care, ATG therapy was initiated with 75 mg of IV rabbit ATG daily for 3 days followed by 50 mg IV for 1 day. Nine days after IV thymoglobulin therapy, he presents with fever, chills, lip swelling, and myalgias. Physical examination revealed mild congestive heart failure and an erythematous and pruritic maculopapular rash. He had tender polyarthritis in his extremities with significant restriction to active and passive range of motion (Fig. 1). Laboratory investigations revealed mild leukocytosis, elevated C-reactive protein, and acute renal insufficiency with no evidence of active sediments on urinalysis. Cytomegalovirus testing was unremarkable. Based on this inflammatory presentation and clinical context, he was diagnosed with SS secondary to IV ATG and started on IV methylprednisolone 1 g daily for 6 days. Failing to show significant improvement at 48 hours, plasmapheresis was initiated for 5 days with marked symptomatic relief after the first exchange. He was discharged home on his 10th day of admission with complete resolution of his presenting symptoms.FIGURE 1: A, Maculo-papular-pruritic rash. B, Limited range of motion on hand grip secondary to arthritis. C, Inflammatory effacement of metacarpophalangeal joints.DISCUSSION Antithymocyte globulins are antibodies used in immunosuppression against human T cells and typically derived from the injection of human thymocytes into animals such as horses and rabbits. Exposure to such heterologous proteins may precipitate SS by the generation of host immunoglobulins and activation of the complement cascade (5). Antithymocyte globulin has been used in human transplantation since the late 1960s and has many inherent benefits (6). It is thought to protect the allograft by dampening inflammatory damage, allorecognition processes, and development and intensity of immune response and may increase the sensibility to oral maintenance immunosuppressive agents (7). The administration of rabbit or horse ATG has been associated with SS in 1% to 10% of cases. Risk factors for developing SS include older age, greater levels of heterologous protein, type of preparation, prior exposure to the antigen or source animal, along with a history of hypergammaglobulinemia and cryoglobulinemia (8–11). Serum sickness is characterized by fever, lymphadenopathy, pruritic rash, polyarthralgias, and polyarthritis, which can develop 7 to 10 days after administration of the exogenous antigen. The maculopapular or urticarial rash is usually the first sign, and in severe cases, patients may develop glomerulonephritis as a conglomeration of immune-complex mediated small vessel vasculitis and tissue injury. Angioedema may also be present (5). The polyarthritis commonly involves large joints, but occasionally, the spine or the temporal-mandibular joint may be affected (8). Laboratory investigations may mirror the clinical inflammatory processes with elevated markers such the ESR and leukocytosis along with hypocomplementemia. The urinalysis may show evidence of glomerulonephritis with hematuria,proteinuria, and red cell casts (5). The clinical presentation of SS can be nonspecific and confused for common conditions, such as acute infections or rheumatism, leading to therapeutic delay (1). Serum sickness is a clinical diagnosis, and therapy should not be delayed for any supportive laboratory results (8). Serum sickness is typically self-limited, resolving spontaneously when the trigger for the immune-inflammatory processes is cleared (5). Given the rarity of this condition, all current treatment recommendations are based on clinical experience and case-based reports. Discontinuation or avoidance of re-exposure to the offending agent is paramount when SS is suspected. In mild cases, treatment can be symptom directed with nonsteroidal anti-inflammatory drugs for arthralgias and fevers, along with antihistamines and topical corticosteroids for the pruritic rash. High-dose oral or IV corticosteroids are reserved for severe forms especially with evidence of disabling symptoms, hemodynamic compromise, glomerulonephritis, and other manifestations of vasculitis (5). High-dose steroids can be administered for 3 days, followed by a rapid prednisone taper with anticipated symptom resolution within 10±2 days (1). Plasma exchange is another treatment modality considered an adjuvant to corticosteroids especially in refractory cases (1, 4). It is often initiated for 1 to 2 exchanges when patients remain symptomatic with minimal improvement after 3 days of corticosteroid use (1). Some investigators even advocate plasma exchange as the initial and only treatment modality for SS (8). Jacques Rizkallah Francisco Cordova Amrit Malik Shelley Zieroth Section of Cardiology Department of Medicine St Boniface Hospital University of Manitoba Winnipeg, Manitoba, Canada." @default.
• W2092895836 created "2016-06-24" @default.
• W2092895836 creator A5009657244 @default.
• W2092895836 creator A5063201946 @default.
• W2092895836 creator A5080474368 @default.
• W2092895836 creator A5087438246 @default.
• W2092895836 date "2012-12-15" @default.
• W2092895836 modified "2023-10-06" @default.
• W2092895836 title "Serum Sickness After Antithymocyte Globulin Administration in a Cardiac Transplant Patient" @default.
• W2092895836 cites W1964381596 @default.
• W2092895836 cites W1965377406 @default.
• W2092895836 cites W1967638197 @default.
• W2092895836 cites W2001628771 @default.
• W2092895836 cites W2033959703 @default.
• W2092895836 cites W2040537348 @default.
• W2092895836 cites W2068115307 @default.
• W2092895836 cites W2069138930 @default.
• W2092895836 cites W2073735473 @default.
• W2092895836 cites W2335055866 @default.
• W2092895836 doi "https://doi.org/10.1097/tp.0b013e318274ab85" @default.
• W2092895836 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23222743" @default.
• W2092895836 hasPublicationYear "2012" @default.
• W2092895836 type Work @default.
• W2092895836 sameAs 2092895836 @default.
• W2092895836 citedByCount "3" @default.
• W2092895836 countsByYear W20928958362013 @default.
• W2092895836 countsByYear W20928958362015 @default.
• W2092895836 countsByYear W20928958362019 @default.
• W2092895836 crossrefType "journal-article" @default.
• W2092895836 hasAuthorship W2092895836A5009657244 @default.
• W2092895836 hasAuthorship W2092895836A5063201946 @default.
• W2092895836 hasAuthorship W2092895836A5080474368 @default.
• W2092895836 hasAuthorship W2092895836A5087438246 @default.
• W2092895836 hasBestOaLocation W20928958361 @default.
• W2092895836 hasConcept C126322002 @default.
• W2092895836 hasConcept C141071460 @default.
• W2092895836 hasConcept C151730666 @default.
• W2092895836 hasConcept C2778198053 @default.
• W2092895836 hasConcept C2778594517 @default.
• W2092895836 hasConcept C2778923028 @default.
• W2092895836 hasConcept C2779343474 @default.
• W2092895836 hasConcept C2911091166 @default.
• W2092895836 hasConcept C71924100 @default.
• W2092895836 hasConcept C86803240 @default.
• W2092895836 hasConcept C90924648 @default.
• W2092895836 hasConceptScore W2092895836C126322002 @default.
• W2092895836 hasConceptScore W2092895836C141071460 @default.
• W2092895836 hasConceptScore W2092895836C151730666 @default.
• W2092895836 hasConceptScore W2092895836C2778198053 @default.
• W2092895836 hasConceptScore W2092895836C2778594517 @default.
• W2092895836 hasConceptScore W2092895836C2778923028 @default.
• W2092895836 hasConceptScore W2092895836C2779343474 @default.
• W2092895836 hasConceptScore W2092895836C2911091166 @default.
• W2092895836 hasConceptScore W2092895836C71924100 @default.
• W2092895836 hasConceptScore W2092895836C86803240 @default.
• W2092895836 hasConceptScore W2092895836C90924648 @default.
• W2092895836 hasIssue "11" @default.
• W2092895836 hasLocation W20928958361 @default.
• W2092895836 hasLocation W20928958362 @default.
• W2092895836 hasLocation W20928958363 @default.
• W2092895836 hasOpenAccess W2092895836 @default.
• W2092895836 hasPrimaryLocation W20928958361 @default.
• W2092895836 hasRelatedWork W196289481 @default.
• W2092895836 hasRelatedWork W1996064426 @default.
• W2092895836 hasRelatedWork W2003938723 @default.
• W2092895836 hasRelatedWork W2047967234 @default.
• W2092895836 hasRelatedWork W2104870143 @default.
• W2092895836 hasRelatedWork W2271522818 @default.
• W2092895836 hasRelatedWork W2439875401 @default.
• W2092895836 hasRelatedWork W2986892476 @default.
• W2092895836 hasRelatedWork W4247718175 @default.
• W2092895836 hasRelatedWork W4253073611 @default.
• W2092895836 hasVolume "94" @default.
• W2092895836 isParatext "false" @default.
• W2092895836 isRetracted "false" @default.
• W2092895836 magId "2092895836" @default.
• W2092895836 workType "article" @default.